Nkarta Inc
Officers & Directors
1. Paul Hastings (President and CEO) 2. Brian Kotzin (Chief Medical Officer) 3. Jared Weiss (Chief Financial Officer) 4. Christina Tartaglia (Chief Operating Officer) 5. Daniel Kaufman (Chief Scientific Officer) Board of Directors: 1. Arthur Tzianabos (Chairman of the Board) 2. Avik Roy 3. Peter Moldt 4. Robert Booth 5. Sean Parker 6
News about Nkarta Inc Key Personnel |
Nkarta's Recent Underwritten Offering and Financial Performance Reflects Volatility in Biopharmaceutical Sector SOUTH SAN FRANCISCO, Calif., March 25, 2024 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company specializing in the development of engineered natural killer (NK) cell therapies, recently announced the pricing of an underwritten offering, aiming to raise $240 million. However, this news comes amid concerns regarding the company's financial performance, particularly with a cumulative net loss of $122 million recorded during the 12 months ending in the third quarter of 2023. This indicates a negative return on investment (ROI) of -29.38%, highlighting potential challenges for investors.
|
|